• O. M. Kovalyova Kharkiv National Medical University, Kharkiv, Ukraine
  • G. V. Kozhemiaka Kharkiv National Medical University, Kharkiv, Ukraine
  • O. V. Honchar Kharkiv National Medical University, Kharkiv, Ukraine
Keywords: osteopontin, interleukin-15, hypertension, left ventricular myocardial dysfunction, chronic heart failure


Based on a survey of 108 patients with hypertension complicated by chronic heart failure, studied the connection concentration of osteopontin, interleukin-15 inserum and morpho-functional characteristics of the left ventricle of the heart. In patients with CHF osteopontin levels were significantly higher, it revealed a relationship between adverse LV filling state and knots in serum osteopontin, while the level of IL-15 did not show such a relationship. The results indicate the potential value of osteopontin as a biomarker for the diagnosis of CHF.

1. In hypertensive patients in combination with CHF revealed significantly elevated levels of osteopontin in the blood serum, reaching maximum severity in patients with heart failure stage II. IL-15 level in these patients does not depend on the presence and severity of heart failure. 2. Increased serum levels of osteopontin in hypertensive patients is associated with a relatively unfavorable LV filling state, both in the early and late in diastole, the manifestation of which is the negative correlation with the values of osteopontin peak E, and a positive attitude to the E/E'. 3. The established relationship concentration of osteopontin in the blood serum with functional myocardial changes in hypertensive patients complicated with heart failure, an opportunity to recognize the important role of this maker of fibrosis in myocardial remodeling and heart failure severity.


Download data is not yet available.

Author Biographies

O. M. Kovalyova, Kharkiv National Medical University, Kharkiv, Ukraine

61022, Kharkiv, 4 Nauky Avenue

G. V. Kozhemiaka, Kharkiv National Medical University, Kharkiv, Ukraine

61022, Kharkiv, 4 Nauky Avenue

O. V. Honchar, Kharkiv National Medical University, Kharkiv, Ukraine

61022, Kharkiv, 4 Nauky Avenue



Ipatov A.V. Osnovni pokaznyky invalidnosti ta diyalnosti medyko-sotsialnykh expertnykh komisiy Ukrayiny za 2015 rik [analitychno – informatsiynyy dovidnyk] / A.V. Ipatov, O.M. Moroz, V.A. Golik. – Dnipropetrovsk: Royal-Print, 2016. – S. 157–158.

Potekhin N.P. Peculiarities of myocardium remodeling in patients with ischemic heart disease and arterial hypertension / N. P. Potekhin, Iu.A. Rozhnov., F.A. Orlov [et al.] // Voen Med Zh. – 2011. - № 332 (2). – P. 30–7.

Samak M. Cardiac Hypertrophy: An Introduction to Molecular and Cellular Basis / M. Samak, J. Fatullayev, A. Sabashnikov // Med Sci Monit Basic Res. – 2016. - № 22. – P. 75–79.

Singh M. Osteopontin: At the cross-roads of myocyte survival and myocardial function / M. Singh, S. Dalal, K. Singh // Life Sci. – 2014. – № 118 (1). – P. 1–6.

Zhao H. Inhibition of osteopontin reduce the cardiac myofibrosis in dilated cardiomyopathy via focal adhesion kinase mediated signaling pathway / H. Zhao, W. Wang, J. Zhang [et al.] // Am J Transl Res. – 2016. – № 9. – P. 3645–3655.

Lezhenko H. A. Factory formirovaniya arterialnoj hypertenzii u detej s ozhyreniem / H. A. Lezhenko, K.V. Gladun, E.E. Pashkova // Dytiachij likar. – 2011. – № 3 (10). – S. 23–34.

Zarrouk-Mahjoub S. Pro- and anti-inflammatory cytokines in post-infarction left ventricular remodeling / S. Zarrouk-Mahjoub, M. Zaghdoudi, Z. Amira [et al.] // Int J Cardiol. – 2016. – № 221. – P. 632–636.

Patidar M. Interleukin 15: A key cytokine for immunotherapy / M. Patidar , N. Yadav, S.K. Dalai // Cytokine Growth Factor Rev. – 2016. – № 7. – P. 1359–1361.

Kavey R.E. Left ventricular hypertrophy in hypertensive children and adolescents: Predictors and prevalence / R.E. Kavey // Curr Hypertens Rep. – 2013. – № 15 (5). – P. 453–457.

Berenji K. Does load-induced ventricular hypertrophy progress to systolic heart failure? / K. Berenji, M.H. Drazner, B.A. Rothermel [et al.] // Am J Physiol Heart Circ Physiol. – 2005. - № 289 (1). – P. 8–16.

Volpe M. Hypertension in Patients with Heart Failure with Reduced Ejection Fraction / M. Volpe, C. Santolamazza, G. Tocci // Curr Cardiol Rep. 2016. – № 18 (12). – P. 127.

Chen X. J. Uncontrolled blood pressure as an independent risk factor of early impaired left ventricular systolic function in treated hypertension / X. J. Chen, X. L. Sun, Q. Zhang // Echocardiography. – 2016. - № 33 (10). – P. 1488–1494.

Singh M. Osteopontin: role in extracellular matrix deposition and myocardial remodeling post-MI / M. Singh, C.R. Foster, S. Dalal [et al.] // J Mol Cell Cardiol. – 2010. - № 48. – P. 538–543.

Rosenberg M. Osteopontin, a new prognostic biomarker in patients with chronic heart failure / M. Rosenberg, C. Zugck, M. Nelles [et al.] // Circ Heart Fail. – 2008. - № 1. – P. 43–49.

Behnes M. Diagnostic and prognostic value of osteopontin in patients with acute congestive heart failure / M. Behnes, M. Brueckmann, S. Lang [et al.] // Eur J Heart Fail. – 2013. - № 15. – P. 1390–1400.

Heymans S. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology / S. Heymans, E. Hirsch, S.D. Anker [et al.] // Eur J Heart Fail. – 2009. - № 11 (2). – P. 119–129.

Kuusisto J. Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy / J. Kuusisto, V. Kärjä, P. Sipola [et al.] // Heart. – 2012. – № 98 (13). – P. 1007–1013.

How to Cite
Kovalyova, O. M., Kozhemiaka, G. V., & Honchar, O. V. (1). OSTEOPONTIN, INTERLEUKIN-15 AND DYSFUNCTION OF LEFT VENTRICULAR MYOCARDIUM IN HYPERTENSIVE PATIENTS WITH CHRONIC HEART FAILURE. The Journal of V. N. Karazin Kharkiv National University, Series "Medicine", (32), 19-23. Retrieved from https://periodicals.karazin.ua/medicine/article/view/7822
Clinical research